Close Menu

Skyline Diagnostics

The genetic test determines risk levels and prognosis for patients with multiple myeloma based on the SKY92 gene signature.

Dutch molecular diagnostics company SkylineDx recently established a presence in Boston to bolster its outreach to the North American market.

SkylineDx has acquired all assets from recently shuttered Skyline Diagnostics and will continue to develop and commercialize the latter's menu of microarray-based tests, BioArray News has learned.

Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009.

This story was originally posted on June 22.

Skyline will collaborate with Janssen to develop a test to identify patients at increased risk of side effects from a multiple myeloma drug.

Skyline will use its expertise and technologies in genetic profiling and bioinformatics to generate and analyze diagnostics information related to an undisclosed compound from Janssen.

New Product Watch: Mar 22, 2011

Premium

Phalanx Biotech's Rat Whole Genome OneArray, Skyline Diagnostics' AMLprofiler

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.